Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases
Rattachement africain : it, ch, be, us, de, cz, ca, mx, in, fr, br. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background Conducting randomized controlled trials to investigate survival in a rare disease like pulmonary arterial hypertension has considerable ethical and logistical constraints. In many studies, such as the Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome (SERAPHIN) randomized controlled trial, evaluating survival is further complicated by bias introduced by allowing active therapy among placebo-treated patients who clinically deteriorate. Methods and Results SERAPHIN enrolled and followed patients in the same time frame as the US Registry to Evaluate Early And Long-term PAH Disease Management, providing an opportunity to compare observed survival for SERAPHIN patients with predicted survival had they received real-world treatment as in the Registry to Evaluate Early And Long-term PAH Disease Management. From the Registry to Evaluate Early And Long-term PAH Disease Management (N=3515), 734 patients who met SERAPHIN eligibility criteria were selected and their data used to build a prediction model for time to death up to 3 years based on 10 baseline prognostic variables. The model was used to predict a survival curve for each of the 742 SERAPHIN patients via their baseline variables. The average of these predicted survival curves was compared with observed survival of the placebo (n=250) and macitentan 10 mg (n=242) groups using a log-rank test and Cox proportional hazard model. Observed mortality risk for patients randomized to placebo, 62% of whom were taking background pulmonary arterial hypertension therapy, tended to be lower than that predicted for all SERAPHIN patients (16% lower; P=0.259). The observed placebo survival curve closely approximated the predicted survival curve for the first 15 months. Beyond that time, observed risk of mortality decreased compared with predicted mortality, potentially reflecting the impact of crossover of patients in the placebo group to active therapy. Over 3 years, risk of mortality observed with macitentan 10 mg was 35% lower than predicted mortality ( P=0.010). Conclusions These analyses show that, in a rare disease, real-world observational data can complement randomized controlled trial data to overcome some challenges associated with assessing survival in the setting of a randomized controlled trial. Clinical Trial Registration https://www.clinicaltrials.gov . Unique identifiers: NCT00660179 and NCT00370214.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases
- Date Crossref
- 01/05/2019
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
European Hospital pays non établi dans la noticeÉtablissement de santé
-
Actelion (Switzerland) pays non établi dans la noticeEntreprise
-
KU Leuven pays non établi dans la noticeUniversité ou école supérieure
-
Boston University Pulmonary Center pays non établi dans la noticeUniversité ou école supérieure
-
Dana-Farber/Harvard Cancer Center pays non établi dans la noticeÉtablissement de santé
-
German Center for Lung Research pays non établi dans la noticeStructure de recherche
-
Universities of Giessen and Marburg Lung Center pays non établi dans la noticeUniversité ou école supérieure
-
Charles University Clinicial Department of Cardiology and Angiology pays non établi dans la noticeUniversité ou école supérieure
-
London Health Sciences Centre pays non établi dans la noticeÉtablissement de santé
-
Instituto Nacional de Cardiología pays non établi dans la noticeStructure de recherche
-
University of California San Diego Medical Center Division of Pulmonary and Critical Care Medicine pays non établi dans la noticeÉtablissement de santé
-
CARE Hospitals Division of Cardiology pays non établi dans la noticeÉtablissement de santé
European Hospital, Actelion (Switzerland) et KU Leuven, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.